PT  - JOURNAL ARTICLE
AU  - Gater, Laura
ED  - Nauck, Michael
TI  - New Therapies: Vildagliptin
DP  - 2006 Sep 01
TA  - MD Conference Express
PG  - 16--16
VI  - 6
IP  - 2
4099  - http://mdc.sagepub.com/content/6/2/16.short
4100  - http://mdc.sagepub.com/content/6/2/16.full
AB  - Vildagliptin, is a dipeptdyl peptidase 4 (DPP-4) inhibitor; DPP-4 is the enzyme that degrades glucagon-like peptide-1 (GLP-1). GLP-1 triggers glucose dependent insulin secretion, inhibits the secretion of glucagon, slows gastric emptying, and influences satiety. GLP-1 has a very short half-life, so by inhibiting the action of DPP-4, GLP-1 remains in its active form for a longer period. This article discusses updates on vildagliptin.